Johnson & Johnson (NYSE:JNJ) is included among the 14 Best Pharma Dividend Stocks to Buy in 2025. Johnson & Johnson (NYSE:JNJ) has long been considered one of the most dependable dividend stocks, ...

JNJ eyes $50B in oncology sales by 2030, driven by drugs like Darzalex, Erleada, new launches including Carvykti and Tecvayli, and its cancer pipeline.

The awards will be handed out at a gala event scheduled for October 9 at New York City’s Cipriani Wall Street.